Table 4.
Univariate and Multivariate Analysis of Risk Factors for Overall Survival and Progression-Free Survival After PSM.
| Characteristics | Overall survival | Progression-free survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
| HR | 95% CI for HR | P | HR | 95% CI for HR | P | HR | 95% CI for HR | P | HR | 95% CI for HR | P | |
| Age, years (<65 vs ≥65) | 1.265 | 0.695-2.302 | .441 | 0.980 | 0.568-1.689 | .941 | ||||||
| Gender (Female vs Male) | 0.759 | 0.355-1.621 | .476 | 0.709 | 0.358-1.402 | .323 | ||||||
| Tumor size, cm (<7 vs ≥7) | 1.381 | 0.795-2.398 | .251 | 1.306 | 0.800-2.130 | .286 | ||||||
| Tumor number, (Single vs Multiple) | 1.074 | 0.608-1.897 | .805 | 0.917 | 0.559-1.504 | .731 | ||||||
| Macrovascular invasion, (No vs Yes) | 1.264 | 0.727-2.197 | .406 | 0.928 | 0.564-1.527 | .769 | ||||||
| Extrahepatic metastasis, (No vs Yes) | 1.219 | 0.698-2.130 | .487 | 1.453 | 0.880-2.399 | .144 | ||||||
| BCLC stage (Stage B vs C) | 1.677 | 0.754-3.731 | .205 | 1.644 | 0.811-3.333 | .168 | ||||||
| Child-Pugh class (Class A vs B) | 2.667 | 1.440-4.940 | .002 | 2.821 | 1.515-5.252 | .001 | 2.183 | 1.232-3.868 | .007 | 2.378 | 1.334-4.239 | .003 |
| ALT, U/L | 1.000 | 0.993-1.006 | .920 | 0.999 | 0.993-1.005 | .663 | ||||||
| AST, U/L | 1.003 | 0.998-1.008 | .258 | 1.001 | 0.996-1.006 | .733 | ||||||
| AFP, ng/mL (<400 vs ≥400) | 1.982 | 1.121-3.504 | .019 | 2.224 | 1.248-3.963 | .007 | 1.479 | 0.903-2.422 | .120 | |||
| Hepatitis B/C, (No vs Yes) | 1.509 | 0.597-3.813 | .385 | 1.395 | 0.635-3.062 | .407 | ||||||
| Liver cirrhosis, (No vs Yes) | 1.351 | 0.574-3.181 | .491 | 1.435 | 0.683-3.013 | .341 | ||||||
| Treatment (PL versus TPL） | 2.023 | 1.148-3.563 | .015 | 2.450 | 1.365-4.398 | .003 | 1.710 | 1.046-2.796 | .033 | 1.841 | 1.119-3.029 | .016 |
Abbreviations: TPL, transarterial chemoembolization combined with PD-1 inhibitors plus lenvatinib; PL, PD-1 inhibitors plus lenvatinib; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha-fetoprotein; HR, hazard rate; CI, confidence interval; PSM, propensity score matching; BCLC, Barcelona Clinic Liver Cancer.